HiveProspectStranded Biotech Asset IntelligenceResearch intelligence
Research workspace tools

Stranded Biotech Asset Intelligence

Find your next diligence question

Find → Filter → Understand → Compare → Watch → Resolve. Discovery priority is not acquisition readiness.

1067 matching exact-name labels; not unique global drugs.

Select 2–10 for a subscription comparison.

UNKNOWN · LOW discovery confidence

Androgen receptor (AR) inhibitor

Reported program or trial event; neither availability nor investment recommendation

Why this survived

Selected for further evidence review: inadequate public evidence. Discovery is not buyer qualification.

MODEL INFERENCE · Source 1
Human SignalUNKNOWN
Cheap TruthUNKNOWN
AcquirabilityUNKNOWN

UNKNOWN

Next Best Diligence Question

What primary evidence resolves human efficacy for Androgen receptor (AR) inhibitor in this exact treatment and indication context?

Why it matters and what could change

Human Signal: human efficacy is UNKNOWN; resolve this component before making a stronger decision.

Evidence needed: Source-bound, dated evidence for human efficacy, including contradictory findings and scope limitations.

Likely source: Official trial arm-level results, primary PubMed human studies and protocols

Continue diligence, deprioritize or retain UNKNOWN; no automatic promotion.

Fatal flaw: Unknown. No known fatal flaw is not asserted without complete scoped review.

Evidence completeness — coverage, not confidence

Human Signal: 0 / 5 gate components adjudicated

Cheap Truth: 0 / 6 gate components adjudicated

Clean Rights: 0 / 6 gate components adjudicated

Market Pull: 0 / 5 gate components adjudicated

Understand this lead →

UNKNOWN · LOW discovery confidence

anti-CD19 CAR-T cells

Reported program or trial event; neither availability nor investment recommendation

Why this survived

Selected for further evidence review: inadequate public evidence. Discovery is not buyer qualification.

MODEL INFERENCE · Source 1
Human SignalUNKNOWN
Cheap TruthUNKNOWN
AcquirabilityUNKNOWN

UNKNOWN

Next Best Diligence Question

What primary evidence resolves human efficacy for anti-CD19 CAR-T cells in this exact treatment and indication context?

Why it matters and what could change

Human Signal: human efficacy is UNKNOWN; resolve this component before making a stronger decision.

Evidence needed: Source-bound, dated evidence for human efficacy, including contradictory findings and scope limitations.

Likely source: Official trial arm-level results, primary PubMed human studies and protocols

Continue diligence, deprioritize or retain UNKNOWN; no automatic promotion.

Fatal flaw: Unknown. No known fatal flaw is not asserted without complete scoped review.

Evidence completeness — coverage, not confidence

Human Signal: 0 / 5 gate components adjudicated

Cheap Truth: 0 / 6 gate components adjudicated

Clean Rights: 0 / 6 gate components adjudicated

Market Pull: 0 / 5 gate components adjudicated

Understand this lead →

UNKNOWN · LOW discovery confidence

anti-CD19 redirected NK cells

Reported program or trial event; neither availability nor investment recommendation

Why this survived

Selected for further evidence review: inadequate public evidence. Discovery is not buyer qualification.

MODEL INFERENCE · Source 1
Human SignalUNKNOWN
Cheap TruthUNKNOWN
AcquirabilityUNKNOWN

UNKNOWN

Next Best Diligence Question

What primary evidence resolves human efficacy for anti-CD19 redirected NK cells in this exact treatment and indication context?

Why it matters and what could change

Human Signal: human efficacy is UNKNOWN; resolve this component before making a stronger decision.

Evidence needed: Source-bound, dated evidence for human efficacy, including contradictory findings and scope limitations.

Likely source: Official trial arm-level results, primary PubMed human studies and protocols

Continue diligence, deprioritize or retain UNKNOWN; no automatic promotion.

Fatal flaw: Unknown. No known fatal flaw is not asserted without complete scoped review.

Evidence completeness — coverage, not confidence

Human Signal: 0 / 5 gate components adjudicated

Cheap Truth: 0 / 6 gate components adjudicated

Clean Rights: 0 / 6 gate components adjudicated

Market Pull: 0 / 5 gate components adjudicated

Understand this lead →

UNKNOWN · UNKNOWN discovery confidence

Anti-CD19-chimeric-antigen-receptor-transduced T cells

Reported program or trial event; neither availability nor investment recommendation

Why this survived

Selected for further evidence review: inadequate public evidence. Discovery is not buyer qualification.

MODEL INFERENCE ·
Human SignalUNKNOWN
Cheap TruthUNKNOWN
AcquirabilityUNKNOWN

UNKNOWN

Next Best Diligence Question

What primary evidence resolves human efficacy for Anti-CD19-chimeric-antigen-receptor-transduced T cells in this exact treatment and indication context?

Why it matters and what could change

Human Signal: human efficacy is UNKNOWN; resolve this component before making a stronger decision.

Evidence needed: Source-bound, dated evidence for human efficacy, including contradictory findings and scope limitations.

Likely source: Official trial arm-level results, primary PubMed human studies and protocols

Continue diligence, deprioritize or retain UNKNOWN; no automatic promotion.

Fatal flaw: Unknown. No known fatal flaw is not asserted without complete scoped review.

Evidence completeness — coverage, not confidence

Human Signal: 0 / 5 gate components adjudicated

Cheap Truth: 0 / 6 gate components adjudicated

Clean Rights: 0 / 6 gate components adjudicated

Market Pull: 0 / 5 gate components adjudicated

Understand this lead →

UNKNOWN · LOW discovery confidence

anti-CD70-CAR-T cells

Reported program or trial event; neither availability nor investment recommendation

Why this survived

Selected for further evidence review: trial-design failure. Discovery is not buyer qualification.

MODEL INFERENCE · Source 1
Human SignalUNKNOWN
Cheap TruthUNKNOWN
AcquirabilityUNKNOWN

UNKNOWN

Next Best Diligence Question

What primary evidence resolves human efficacy for anti-CD70-CAR-T cells in this exact treatment and indication context?

Why it matters and what could change

Human Signal: human efficacy is UNKNOWN; resolve this component before making a stronger decision.

Evidence needed: Source-bound, dated evidence for human efficacy, including contradictory findings and scope limitations.

Likely source: Official trial arm-level results, primary PubMed human studies and protocols

Continue diligence, deprioritize or retain UNKNOWN; no automatic promotion.

Fatal flaw: Unknown. No known fatal flaw is not asserted without complete scoped review.

Evidence completeness — coverage, not confidence

Human Signal: 0 / 5 gate components adjudicated

Cheap Truth: 0 / 6 gate components adjudicated

Clean Rights: 0 / 6 gate components adjudicated

Market Pull: 0 / 5 gate components adjudicated

Understand this lead →

UNKNOWN · LOW discovery confidence

anti-PD-1 antibody

Reported program or trial event; neither availability nor investment recommendation

Why this survived

Selected for further evidence review: inadequate public evidence. Discovery is not buyer qualification.

MODEL INFERENCE · Source 1
Human SignalUNKNOWN
Cheap TruthUNKNOWN
AcquirabilityUNKNOWN

UNKNOWN

Next Best Diligence Question

What primary evidence resolves human efficacy for anti-PD-1 antibody in this exact treatment and indication context?

Why it matters and what could change

Human Signal: human efficacy is UNKNOWN; resolve this component before making a stronger decision.

Evidence needed: Source-bound, dated evidence for human efficacy, including contradictory findings and scope limitations.

Likely source: Official trial arm-level results, primary PubMed human studies and protocols

Continue diligence, deprioritize or retain UNKNOWN; no automatic promotion.

Fatal flaw: Unknown. No known fatal flaw is not asserted without complete scoped review.

Evidence completeness — coverage, not confidence

Human Signal: 0 / 5 gate components adjudicated

Cheap Truth: 0 / 6 gate components adjudicated

Clean Rights: 0 / 6 gate components adjudicated

Market Pull: 0 / 5 gate components adjudicated

Understand this lead →

UNKNOWN · LOW discovery confidence

Anti-PSMA Designer T Cells

Reported program or trial event; neither availability nor investment recommendation

Why this survived

Selected for further evidence review: financing failure. Discovery is not buyer qualification.

MODEL INFERENCE · Source 1
Human SignalUNKNOWN
Cheap TruthUNKNOWN
AcquirabilityUNKNOWN

UNKNOWN

Next Best Diligence Question

What primary evidence resolves human efficacy for Anti-PSMA Designer T Cells in this exact treatment and indication context?

Why it matters and what could change

Human Signal: human efficacy is UNKNOWN; resolve this component before making a stronger decision.

Evidence needed: Source-bound, dated evidence for human efficacy, including contradictory findings and scope limitations.

Likely source: Official trial arm-level results, primary PubMed human studies and protocols

Continue diligence, deprioritize or retain UNKNOWN; no automatic promotion.

Fatal flaw: Unknown. No known fatal flaw is not asserted without complete scoped review.

Evidence completeness — coverage, not confidence

Human Signal: 0 / 5 gate components adjudicated

Cheap Truth: 0 / 6 gate components adjudicated

Clean Rights: 0 / 6 gate components adjudicated

Market Pull: 0 / 5 gate components adjudicated

Understand this lead →

UNKNOWN · LOW discovery confidence

Antiarrhythmic Drug Therapy

Reported program or trial event; neither availability nor investment recommendation

Why this survived

Selected for further evidence review: inadequate public evidence. Discovery is not buyer qualification.

MODEL INFERENCE · Source 1
Human SignalUNKNOWN
Cheap TruthUNKNOWN
AcquirabilityUNKNOWN

UNKNOWN

Next Best Diligence Question

What primary evidence resolves human efficacy for Antiarrhythmic Drug Therapy in this exact treatment and indication context?

Why it matters and what could change

Human Signal: human efficacy is UNKNOWN; resolve this component before making a stronger decision.

Evidence needed: Source-bound, dated evidence for human efficacy, including contradictory findings and scope limitations.

Likely source: Official trial arm-level results, primary PubMed human studies and protocols

Continue diligence, deprioritize or retain UNKNOWN; no automatic promotion.

Fatal flaw: Unknown. No known fatal flaw is not asserted without complete scoped review.

Evidence completeness — coverage, not confidence

Human Signal: 0 / 5 gate components adjudicated

Cheap Truth: 0 / 6 gate components adjudicated

Clean Rights: 0 / 6 gate components adjudicated

Market Pull: 0 / 5 gate components adjudicated

Understand this lead →

UNKNOWN · LOW discovery confidence

Antibiotic

Reported program or trial event; neither availability nor investment recommendation

Why this survived

Selected for further evidence review: inadequate public evidence. Discovery is not buyer qualification.

MODEL INFERENCE · Source 1
Human SignalUNKNOWN
Cheap TruthUNKNOWN
AcquirabilityUNKNOWN

UNKNOWN

Next Best Diligence Question

What primary evidence resolves human efficacy for Antibiotic in this exact treatment and indication context?

Why it matters and what could change

Human Signal: human efficacy is UNKNOWN; resolve this component before making a stronger decision.

Evidence needed: Source-bound, dated evidence for human efficacy, including contradictory findings and scope limitations.

Likely source: Official trial arm-level results, primary PubMed human studies and protocols

Continue diligence, deprioritize or retain UNKNOWN; no automatic promotion.

Fatal flaw: Unknown. No known fatal flaw is not asserted without complete scoped review.

Evidence completeness — coverage, not confidence

Human Signal: 0 / 5 gate components adjudicated

Cheap Truth: 0 / 6 gate components adjudicated

Clean Rights: 0 / 6 gate components adjudicated

Market Pull: 0 / 5 gate components adjudicated

Understand this lead →

UNKNOWN · UNKNOWN discovery confidence

Antigen-Escalation Stage

Reported program or trial event; neither availability nor investment recommendation

Why this survived

Selected for further evidence review: inadequate public evidence. Discovery is not buyer qualification.

MODEL INFERENCE ·
Human SignalUNKNOWN
Cheap TruthUNKNOWN
AcquirabilityUNKNOWN

UNKNOWN

Next Best Diligence Question

What primary evidence resolves human efficacy for Antigen-Escalation Stage in this exact treatment and indication context?

Why it matters and what could change

Human Signal: human efficacy is UNKNOWN; resolve this component before making a stronger decision.

Evidence needed: Source-bound, dated evidence for human efficacy, including contradictory findings and scope limitations.

Likely source: Official trial arm-level results, primary PubMed human studies and protocols

Continue diligence, deprioritize or retain UNKNOWN; no automatic promotion.

Fatal flaw: Unknown. No known fatal flaw is not asserted without complete scoped review.

Evidence completeness — coverage, not confidence

Human Signal: 0 / 5 gate components adjudicated

Cheap Truth: 0 / 6 gate components adjudicated

Clean Rights: 0 / 6 gate components adjudicated

Market Pull: 0 / 5 gate components adjudicated

Understand this lead →

UNKNOWN · LOW discovery confidence

Antihistamine

Reported program or trial event; neither availability nor investment recommendation

Why this survived

Selected for further evidence review: financing failure. Discovery is not buyer qualification.

MODEL INFERENCE · Source 1
Human SignalUNKNOWN
Cheap TruthUNKNOWN
AcquirabilityUNKNOWN

UNKNOWN

Next Best Diligence Question

What primary evidence resolves human efficacy for Antihistamine in this exact treatment and indication context?

Why it matters and what could change

Human Signal: human efficacy is UNKNOWN; resolve this component before making a stronger decision.

Evidence needed: Source-bound, dated evidence for human efficacy, including contradictory findings and scope limitations.

Likely source: Official trial arm-level results, primary PubMed human studies and protocols

Continue diligence, deprioritize or retain UNKNOWN; no automatic promotion.

Fatal flaw: Unknown. No known fatal flaw is not asserted without complete scoped review.

Evidence completeness — coverage, not confidence

Human Signal: 0 / 5 gate components adjudicated

Cheap Truth: 0 / 6 gate components adjudicated

Clean Rights: 0 / 6 gate components adjudicated

Market Pull: 0 / 5 gate components adjudicated

Understand this lead →

UNKNOWN · LOW discovery confidence

Apomorphine

Reported program or trial event; neither availability nor investment recommendation

Why this survived

Selected for further evidence review: inadequate public evidence. Discovery is not buyer qualification.

MODEL INFERENCE · Source 1
Human SignalUNKNOWN
Cheap TruthUNKNOWN
AcquirabilityUNKNOWN

UNKNOWN

Next Best Diligence Question

What primary evidence resolves human efficacy for Apomorphine in this exact treatment and indication context?

Why it matters and what could change

Human Signal: human efficacy is UNKNOWN; resolve this component before making a stronger decision.

Evidence needed: Source-bound, dated evidence for human efficacy, including contradictory findings and scope limitations.

Likely source: Official trial arm-level results, primary PubMed human studies and protocols

Continue diligence, deprioritize or retain UNKNOWN; no automatic promotion.

Fatal flaw: Unknown. No known fatal flaw is not asserted without complete scoped review.

Evidence completeness — coverage, not confidence

Human Signal: 0 / 5 gate components adjudicated

Cheap Truth: 0 / 6 gate components adjudicated

Clean Rights: 0 / 6 gate components adjudicated

Market Pull: 0 / 5 gate components adjudicated

Understand this lead →